When it comes to starting a company, few rise from humble beginnings to reshape the industry. Mankind Pharma is one such name, leading the list of top 10 pharmaceutical companies in India. Despite its relatively recent entry into the sector, it has quickly become a leading name in prescriptions, ranking 3rd in product volume and managing 23 influential brand families. How did Mankind Pharma Limited build such a strong reputation so swiftly?
Join us as we rewind to the early days and meet the visionaries who started mankind pharma limited.
Mankind Pharma History: From Its Early Days to Global Success
So, this goes back to the year 1991. The company was born to Ramesh Juneja and his younger brother Rajeev Juneja. The operations office began in 1995 with a team of just 53 Medical Representatives and Managers. They indeed had big dreams.
Over nearly two decades, this small team has evolved into one of India’s top 10 pharmaceutical companies. Their journey is a tale of vision, growth, and relentless pursuit of better healthcare.
Let’s dive into how this incredible transformation unfolded.
In 2004, Mankind Pharma made its mark in the chronic pharmaceutical segment by launching ‘Amlokind’ and ‘Glimestar’ tablets.
This was a significant step forward in their journey to enhance healthcare.
By 2005, the company had set up its first manufacturing facility in Paonta Sahib, Himachal Pradesh. This year also saw Mankind enter the ophthalmic pharmaceutical segment with the introduction of Lubistar and Tobstart eye drops.
The following year, 2007, marked an exciting expansion.
Mankind ventured into the consumer healthcare segment with the launch of the ‘Manforce’ brand. They also made their entry into the animal healthcare sector with Bandykind and Cefticore.
In 2009, Mankind opened a new manufacturing unit at Unit 2, Paonta Sahib.
As 2010 arrived, Mankind introduced the ‘Preganews’ brand. This indeed was something new for indians.
The year 2012 was a milestone with the establishment of Mankind’s first R&D center at IMT Manesar, Haryana.
In 2014, Mankind continued its growth by acquiring Shree Jee Laboratory Private Limited and opening a new manufacturing facility at Unit III, Paonta Sahib.
Mankind Pharma had expanded its global presence with subsidiaries established in the US and Singapore, by 2015.
2017 saw the opening of another manufacturing facility, this time in Sikkim.
As 2019 unfolded, Mankind entered the female infertility segment. The company launched Dydroboon tablets, broadening its therapeutic offerings.
In 2020, Mankind Pharma further expanded its horizons by incorporating Lifestar Pharmaceuticals Private Limited in Nepal. It also entered new specialty therapeutic areas, launching ‘Cilaheart’ and ‘Epifast’ tablets for cardiovascular drugs.
The year 2021 brought more milestones.
The company established Mankind Pharma FZ LLC in Dubai, marking its continued global expansion.
2022 was a year of strategic acquisitions and new ventures. Mankind acquired pharmaceutical formulation brands from Panacea Biotec and entered the oncology segment. This year also saw the acquisition of brands named Daffy and Combihale from Dr. Reddy’s.
In 2023, Mankind achieved a significant milestone by getting listed on NSE and BSE. They also launched international quality API products and in-licensed Symbicort from AstraZeneca.
In the current year, Mankind Pharma has achieved significant milestones.
Here are the key achievements and strategic moves for 2023-2024
- IPO Milestone: Mankind Pharma went public in April 2023.
- Acquisition of Bharat Serums and Vaccines: Mankind Company announced the acquisition of Bharat Serums and Vaccines for around ₹13,630 cr.
- Fundraising Initiative: It has raised over ₹9,000 crore through non-convertible debentures (NCDs) and short-term commercial paper to support the Bharat Serums acquisition.
- New Product Launches: Introduced two new products in the US, taking the total to 41.
Wondering what does Mankind Pharma do? Have a look at the company details!
Mankind Pharma: Transforming Healthcare with Innovative Solutions
Mankind Pharma offers a broad range of therapeutic products, including those for cardiovascular health, antibiotics, gastrointestinal issues, allergies, fungal infections, nutritional needs, NSAIDs, orthopedics, and gynecology. Every day, 7.5 million Indians use Mankind’s cardiac care products. The company has introduced several products such as Placida, Zolahart, and Overzyme. Mankind Pharma company now has a dedicated field force of over 1,968 professionals.
Financial Highlights and Key Information:
- Mankind Pharma Owner: Mr Ramesh Juneja and Mr Rajeev Juneja
- Mankind Pharma Products: Formulations across acute and chronic therapeutic areas. They also serve anti-infectives, cardiovascular, gastrointestinal, neuro/CNS, vitamins, minerals, nutrients, and respiratory treatments.
Prescription Medicines: Anti-infectives, cardiovascular, gastrointestinal, anti-diabetic, neuro/CNS, vitamins/minerals/nutrients, and respiratory.
Consumer Healthcare: Condoms (Manforce), pregnancy detection kits (Prega News), oral contraceptives, antacid powders, vitamin and mineral supplements, and anti-acne preparations.
- Mankind Pharma Net Worth: The total net worth of Mankind Pharma’s products are as follows:
Moxikind-CV (Rs. 2175 million), Telmikind (Rs. 2644 million), Amlokind (Rs. 1903 million), Nurokind (Rs. 1322 million), Cefakind (Rs. 950 million) and Zenflox (Rs. 781 million).
Mankind Pharma Company Financial Highlights Q1FY25
- Mankind Pharma’s revenue grew by 12% YoY to INR 2,893 crore in Q1 FY25.
- Domestic revenue increased by 9% YoY to INR 2,634 crore.
- Exports saw a significant rise of 62% YoY to INR 259 crore.
- EBITDA margin stood at 23.7%, with adjusted EBITDA margin at 25.2%.
- PAT margin for the quarter was 18.8%.
- Diluted EPS increased by 10% YoY to INR 13.4.
Mankind Pharma’s Approach to EHS: Safeguarding Health and the Environment
Mankind Pharma is dedicated to environmental sustainability and safety. It follows policies that ensure it meets all legal requirements while keeping its employees and facilities safe. Many of its manufacturing sites are certified with ISO 14001:2015 (for environmental management) and ISO 45001:2018 (for health and safety).
The company follows strict rules to prevent water and air pollution. It also works to reduce workplace accidents and health risks through careful risk assessments, employee training, and safety checks. Mankind Pharma constantly improves its safety systems to protect its employees and maintain a safe work environment.
Reaching Across Continents: Mankind Pharma’s Global Presence
- Latin America: Peru, Chile, Jamaica, Panama
- South East Asia: Philippines, Malaysia, Cambodia, Myanmar
- Asia: Sri Lanka, Nepal, Maldives, Afghanistan
- Africa: Zimbabwe, Kenya, Tanzania, Zambia, Nigeria, Ghana, Uganda, Rwanda, Ethiopia, Benin, Burkina Faso, Ivory Coast, Mali, Senegal
- CIS (Commonwealth of Independent States): Russian Federation, Ukraine, Moldova, Kazakhstan, Uzbekistan
FAQs| Mankind Pharma Industry
Mankind Pharma is owned by the brothers, Ramesh C. Juneja and Rajeev Juneja.
It is the fourth-largest pharmaceutical company in India based on domestic sales.
The company employs over 22,000 people, 1,968 professionals, and operates 25 factories in India, and servs 300+ products to ver 34 countries.
Sun Pharmaceutical Industries Ltd. is the largest pharmaceutical company in India by market cap and revenue.
Mankind Pharma is known for its wide range of products, including antibiotics, consumer healthcare items like Manforce condoms, and Prega News pregnancy test kits.
The company’s headquarters is in Okhla Phase III, New Delhi, India.
______________________________________________________________________________________
Disclaimer: Investments in the securities market are subject to market risks; read all the related documents carefully before investing.